Bluebird Bio (BLUE) said Friday it agreed to be acquired by Carlyle Group (CG) managed funds and SK Capital Partners.
Under the terms of the deal, bluebird shareholders will receive $3.00 per share in cash and a contingent value of $6.84 per share, payable in cash if bluebird's current product portfolio earns $600 million in net sales in any trailing 12-month period before or ending on Dec. 31, 2027.
Shares slumped 41% following a surge in intraday trading volume to over 4.5 million from a daily average of about 392,000.
AXT (AXTI) reported a wider Q4 non-GAAP loss late Thursday compared with a year ago and sequentially. Wedbush adjusted AXT's price target to $4.50 from $5.50 while maintaining its outperform rating.
Shares of AXT sank 31%, with intraday trading volume catapulting to over 5.3 million versus a daily average of about 361,000.
Akamai Technologies (AKAM) has "limited" short-term growth opportunities, BofA Securities said in a note Friday, following the company's Q4 results overnight. BofA downgraded Akamai to neutral from buy and cut its price target to $100 from $125.
Shares fell 20%, with intraday trading volume surging to over 13.6 million versus a daily average of about 1.7 million.
Price: 4.15, Change: -2.90, Percent Change: -41.12
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.